WO2025232711 - NEW DEUTERIUM-CONTAINING PYRAZOLONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/232711
Publication Date
13.11.2025
International Application No.
PCT/CN2025/092791
International Filing Date
06.05.2025
Title **
[English]
NEW DEUTERIUM-CONTAINING PYRAZOLONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
[French]
NOUVEAU COMPOSÉ PYRAZOLONE CONTENANT DU DEUTÉRIUM, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉES
[Chinese]
一种新型含氘的吡唑啉酮化合物及其药物组合物和用途
Applicants **
NANJING ZHIHE MEDICINE TECHNOLOGY CO., LTD.
Inventors
ZHANG, Zhefeng
MENG, Yuelei
HOU, Wen
Priority Data
202410550297.2
06.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1719 | |
| EPO | Filing, Examination, Granting | 12297 | |
| Japan | Filing, Examination, Granting | 1975 | |
| South Korea | Filing, Examination, Granting | 1642 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,373
Abstract[English]
Disclosed are a new deuterium-containing pyrazolone compound, and a pharmaceutical composition and the use thereof. The new deuterium-containing pyrazolone compound is as represented by formula (I) and/or formula (II), wherein the definition of each substituent is detailed in the description. The compound can be used in the preparation of a drug for preventing or treating neurodegenerative diseases and cardiovascular and cerebrovascular diseases.[French]
L'invention concerne un nouveau composé pyrazolone contenant du deutérium, une composition pharmaceutique et son utilisation. Le nouveau composé pyrazolone contenant du deutérium est tel que représenté par la formule (I) et/ou la formule (II), la définition de chaque substituant étant détaillée dans la description. Le composé peut être utilisé dans la préparation d'un médicament pour la prévention ou le traitement de maladies neurodégénératives et de maladies cardiovasculaires et cérébrovasculaires.[Chinese]
公开了一种新型含氘的吡唑啉酮化合物及其药物组合物和用途，所述新型含氘的吡唑啉酮化合物如式(I)和/或式(Ⅱ)所示，其中各取代基的定义详见说明书；该化合物可用于制备预防或治疗神经病变性疾病、心脑血管疾病的药物。